CAI vs ECL · rev $216.8M vs P/E 35, rev $4.01B
Caris Life Sciences, Inc. Common Stock (CAI) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
CAI currently screens at market cap $5.22B. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the CAI and ECL stock pages for the full models.
Not investment advice.